Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
GSK's Jideytro (zidesamtinib) received FDA approval for previously treated ROS1-positive non-small cell lung cancer based on positive ARROS-1 phase I/II trial data showing durable responses in patients with locally advanced or metastatic disease.
Clinical Trial Data
Phase
I/II
Primary Endpoint
Met
Outcome Details
FDA approval for ROS1-positive NSCLC based on ARROS-1 phase I/II trial data
Importance:8/10
Sentiment:
0.85
FDA approvaloncologylung cancerROS1-positiveNSCLC
Related Companies
Read the original article
Published by PR Newswire Biotech on July 22, 2026 5:58 PM